Heavyweight Sipp Release . . . The first "2019-2020 China's pharmaceutical and health investment value list."

On August 13, 2020, the first "China Pharmaceutical health investment value list 2019-2020" was announced.
This year's ranking includes "China's Pharmaceutical Health's Most Investment Value List" and "China's Pharmaceutical Health's Most Investment Potential List", the former by industry into pharmaceutical manufacturing, medical devices, medical services and third-party services 3 sub-lists.
ceremony held at the Capital Summit, Mr. Cheng Jie, Managing Director of CITIC Securities, Ms. Sun Wei, Assistant President of Guosheng Securities, and Mr. Su Talent, Vice President of Zhongkang Information, presented awards to selected representatives of pharmaceutical and health listed companies.
China Pharmaceutical Health Most Investment Value List Final List Most Investment Value List Award Site China Pharmaceutical Health Most Investment Potential List Final List Most Investment Potential List Award Site 014 success factors become the model basis, objective data and voting results combined with this China Pharmaceutical Investment Value List is mainly for A-shares and Hong Kong stocks of China Pharmaceutical Health listed enterprises, through the previous model to establish, screen candidates and voting and other links to screen out the winning listed enterprises.
This ranking is based on the four basic elements of enterprise security, enterprise growth ability, key success factors and market attractiveness, according to the characteristics of the sub-sectors to tailor, develop scoring models, obtain scoring data and obtain candidate lists.
Chart 1: Enterprise Scoring Model Data Source: In order to make the selection process more scientific, Zhongkang Information not only organized the vast number of investors in the pharmaceutical and health industry to rate the four basic elements of the candidates, but also invited 20 professional fund investors in the pharmaceutical and health industry to vote on the list.
, companies get ratings based on objective data and a 50% share of subjective voting, thus screening out winning companies.
After strict screening, Hengrui Pharmaceuticals, Meirui Medical and other 35 pharmaceutical and health enterprises were selected in the final list, including 10 pharmaceutical manufacturing enterprises, 10 medical device enterprises, 5 medical and third-party service enterprises and 10 of the most investment value enterprises.
selected enterprises in 2019 total market value of 2066.5 billion yuan, accounting for about 33% of the total market value of the A-share and H-share pharmaceutical industry, operating income reached 303.476 billion yuan, accounting for 10.37 percent, net profit of 37.516 billion yuan, accounting for 26.49 percent.
of the winning companies in the industry is obvious.
Chart 2:30 listed enterprises market value, operating income, net profit as a proportion of the total market value data sources: Tonghuashun, Zhongkang Industrial Capital Research Center 02 capital injection into the market, industry competition upgrading due to the aging of the population and other factors, as well as the promotion of medical reform policy, China's pharmaceutical and health industry has maintained rapid development.
industry has attracted the attention of the capital market, in 2019, the total market value of pharmaceutical and biological industry stocks reached 10.79 percent, ranking second in all industries, up 22.15 percent year-on-year.
, China Health Information on the past 20 years, the pharmaceutical and health industry A stock market value of the top 10 enterprises and the sub-sectors.
In terms of enterprises, the list of top 10 companies in 2000, 2010 and 2020 has changed significantly, and none of them has been in the top 10 in terms of total market capitalization in all three years;
Chart 3: In the past 20 years, the top ten pharmaceutical and biological enterprises in total market value continued to adjust data sources: Tonghuashun, Zhongkang Industrial Capital Research Center, therefore, with the changes and upgrading of the industry, enterprises in the capital market is also ups and downs.
medical biology industry has broad room for development, but there are also greater investment risks.
refore, in order to highlight the benchmark enterprises in the pharmaceutical and health industry in the capital market and provide new investment strategy reference from the industry perspective, Zhongkang Information has set up this "2019-2020 China Pharmaceutical and Health Investment Value Ranking".
.